Full Press Release Details
MELBOURNE, Australia and INDIANAPOLIS, Ind. , Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX , Telix, the Company) today announces its financial results for the year ended 31 December 2024 . All figures are in AU$ unless stated otherwise.
FY2024 highlights
For a full list of operational achievements, please refer to the Telix 2024 Annual Report .
| 1. All comparisons to Full Year 2023 results. |
| 2. Previously stated guidance of AU$745 million to AU$776 million (US$490 million to US$510 million). |
| 3. Adjusted EBITDA excludes one-off expenses related to both the Company's U.S. capital markets activity ($9.1 million) and strategic acquisitions ($8.2 million). |
| 4. Launch and brand names subject to regulatory approval. |
| 5. Fibroblast activation protein. Transaction subject to customary closing conditions. |
| 6. RLS acquisition completed 27 January 2025, subsequent to year end. Refer to ASX disclosure. |
| 7. Good manufacturing practice. |
| Summary Group financial results | |||
| Full Year 2024 | Full Year 2023 | ||
| AU$M | AU$M | % change | |
| Revenue | 783.2 | 502.5 | 56 % |
| Cost of sales | (273.6) | (188.2) | 45 % |
| Gross profit | 509.6 | 314.3 | 62 % |
| Research and development (R&D) | (194.6) | (128.5) | 51 % |
| Selling and marketing | (85.5) | (50.1) | 71 % |
| Manufacturing and distribution | (25.7) | (9.9) | 160 % |
| General and administration | (129.8) | (74.2) | 75 % |
| Other gains/(losses) (net) | 8.1 | (35.9) | * |
| Operating profit | 82.1 | 15.7 | 423 % |
| Profit after tax | 49.9 | 5.2 | 860 % |
| Adjusted EBITDA 1 | 99.3 | 58.4 | 70 % |
| Cash from operating activities | 43.0 | 23.9 | 80 % |
| 1. Earnings before interest, tax, depreciation and amortization. |
Group CEO, Dr. Christian Behrenbruch, commented on the result:
Further details on the Company's results can be found in the Appendix 4E, investor presentation, and 2024 Annual Report lodged with the ASX and also available on the Company's website.
Telix provides FY2025 revenue guidance of $1.18 billion to $1.23 billion ( US$770 million to US$800 million 1 ). This guidance includes revenue from Illuccix (in jurisdictions with a marketing authorization) 2 and 11 months of revenue from RLS (and excluding RLS revenue generated from Illuccix). Guidance does not reflect revenue for products that have not yet received a marketing authorization (for example, Gozellix, Pixclara and Zircaix 3 ).
Telix has also provided R&D expenditure guidance, expecting an increased investment range of 20% to 25% compared to FY2024.
An investor webcast will be held at 9.00am AEDT on Friday 21 February 2025 ( 5.00pm EST , Thursday 20 February 2025 ).
Participants can register for the webcast and find audio call details at the following link: https://s1.c-conf.com/ diamondpass/10044775-kmnuu.html
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Canada , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX ).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn , X and Facebook .
| 1. Conversion to US$ is at an average exchange rate of AU$1 = US$0.65 |
| 2. Does not include European countries for which national phase approval has not yet been granted. |
| 3. Launch and brand names subject to regulatory approval. |
Telix Investor Relations
Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: [email protected]
Guidance Disclaimer
The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States . The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Telix uses various non-IFRS information to reflect its underlying performance. For further information, the reconciliation of non-IFRS financial information to Telix's statutory measures, reasons for usefulness and calculation methodology, please refer to the Alternative performance measures section in Telix's Annual Report.
